Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Published Online
on July 2, 2009

Arteriosclerosis, Thrombosis, and Vascular Biology. 2009
Published online before print July 2, 2009, doi: 10.1161/ATVBAHA.109.189514
A more recent version of this article appeared on October 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
29/10/1565    most recent
ATVBAHA.109.189514v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Wu, J.
Right arrow Articles by Fay, W. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, J.
Right arrow Articles by Fay, W. P.

Submitted on April 17, 2009
Accepted on June 20, 2009

Recombinant Plasminogen Activator Inhibitor-1 Inhibits Intimal Hyperplasia

Jianbo Wu *; Lin Peng ; Grainne A. McMahon ; Daniel A. Lawrence ; and William P. Fay

From the Departments of Internal Medicine and Medical Pharmacology & Physiology (J.W., L.P., W.P.F.), University of Missouri School of Medicine, and Research Service, Harry S. Truman Memorial Veterans Affairs Hospital, Columbia; and the Department of Internal Medicine (G.A.M., D.A.L.), University of Michigan Medical School, Ann Arbor.

* To whom correspondence should be addressed. E-mail: wuji{at}health.missouri.edu.

Objective—Plasminogen activator inhibitor-1 (PAI-1) overexpression is implicated in vascular disease. However, the effects of a primary increase in PAI-1 expression on arterial remodeling are poorly defined. We tested the hypothesis that recombinant PAI-1 inhibits intimal hyperplasia after vascular injury.

Methods and Results—Rats underwent carotid artery injury and received intraperitoneal injections of saline or mutant forms of PAI-1 for 14 days, including an active stable mutant (PAI-1-14-1b), a mutant lacking anti-PA activity (PAI-1-R), or a mutant defective in vitronectin (VN) binding (PAI-1-K). All forms of PAI-1 significantly inhibited neointima formation, whereas elastase-cleaved PAI-1, which lacks both anti-PA and VN-binding functions, did not. Similar effects were observed in a murine model. However, the antiproliferative effect of PAI-1-R was lost in Vn-/- mice, suggesting that PAI-1 can inhibit intimal hyperplasia in vivo by a VN-dependent pathway not involving direct inhibition of proteases. In vitro, recombinant PAI-1 inhibited wild-type vascular smooth muscle cell (VSMC) proliferation, promoted apoptosis, and inhibited migration. These effects were lost in VN-deficient VSMCs.

Conclusion—Recombinant PAI-1 inhibits intimal hyperplasia by inhibiting proteases and binding VN. VN is a key determinant of the antiproliferative effect of PAI-1 overexpression. PAI-1-R has therapeutic potential to inhibit vascular restenosis without promoting thrombosis.
Key words: plasminogen activator inhibitor-1 • vitronectin • neointima • vascular smooth muscle cell






ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search
Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited.